Approved indications: Temozolomide is approved to treat newly diagnosed glioblastoma multiforme in adults in combination with radiotherapy followed by maintenance monotherapy, and to treat refractory or relapsed anaplastic astrocytoma in adults and pediatric patients 3 years and older.

Off‑label uses: Clinicians may use temozolomide off‑label for other high‑grade gliomas (such as anaplastic oligodendroglioma), low‑grade gliomas, metastatic brain tumors, and some rare tumors; supporting evidence ranges from phase II trials to observational studies, and use is typically guided by neuro‑oncology specialist recommendations and tumor molecular features.

Efficacy expectations: In newly diagnosed glioblastoma, adding temozolomide to radiation modestly improves median survival and the chance of being alive at 2 years compared with radiation alone, especially when the tumor has MGMT promoter methylation; responses in anaplastic astrocytoma and other high‑grade gliomas can include tumor shrinkage or disease stabilization, but cure is uncommon and benefits are usually measured in additional months to years of survival.

Onset and comparison: Effects are not usually felt as symptom relief right away; imaging over several months is needed to judge benefit, and compared with older nitrosourea‑based regimens, temozolomide is generally at least as effective, better tolerated, and easier to administer because it is taken orally.

Typical dosing: For newly diagnosed glioblastoma in adults, temozolomide is usually given at 75 mg/m² by mouth once daily during radiotherapy for up to 42 days, followed after a break by maintenance cycles of 150–200 mg/m² once daily on days 1–5 of a 28‑day cycle; for recurrent or refractory anaplastic astrocytoma and other high‑grade gliomas, common regimens also use once‑daily dosing on days 1–5 every 28 days, with doses adjusted for blood counts and tolerance.

How to take: Swallow capsules whole with a glass of water, without opening or crushing them; they are often taken on an empty stomach or at bedtime to help reduce nausea, as directed by the oncology team, and anti‑nausea medicine is frequently prescribed to take before the dose.

Special instructions: Doses are calculated based on body surface area and adjusted for side effects, particularly low blood counts, and some patients receiving prolonged treatment or concurrent steroids may be given preventive antibiotics to reduce the risk of certain lung infections; handling precautions are important because temozolomide is a hazardous drug.

Missed dose: If a dose is missed, patients should follow the instructions from their oncology team—typically not doubling up the next day—and should call the clinic promptly for guidance rather than making changes on their own.

Overdose: Taking more than prescribed can cause severe and sometimes prolonged bone‑marrow suppression and other toxicities; suspected overdose is a medical emergency and requires immediate contact with the prescribing oncologist or emergency services, bringing the medication container to help guide care.

Common side effects: Very common effects include nausea, vomiting, loss of appetite, constipation or diarrhea, fatigue, headache, and hair thinning; lowered blood counts (especially neutropenia and thrombocytopenia) occur frequently after each cycle and can cause increased infection risk, easy bruising, or bleeding.

Serious or rare adverse effects: Serious problems that need urgent medical attention include fever or chills, signs of infection, unusual bruising or bleeding, severe or persistent vomiting, shortness of breath, severe fatigue, severe rash or blistering skin reactions, allergic reactions, and, rarely, severe liver injury or opportunistic infections such as Pneumocystis pneumonia when used with prolonged steroids.

Warnings and precautions: Temozolomide can harm an unborn baby and is not recommended in pregnancy; reliable contraception is advised for both men and women during treatment and for a period after the last dose, and breastfeeding is usually not recommended while taking this drug. Extra caution and possible dose adjustment are needed in people with significant liver or kidney impairment, in older adults who may be more prone to low blood counts, and in anyone with a history of severe myelosuppression or serious infections.

Safety compared with other drugs: Compared with some older brain‑tumor chemotherapies, temozolomide is generally better tolerated and causes fewer non‑blood‑related side effects, but it still carries a significant risk of bone‑marrow suppression and infection, so close monitoring is essential.

Monitoring, reporting, and safety updates: Regular blood tests are required, especially before each cycle, to monitor white blood cells, platelets, and liver function, and dosing may be delayed or reduced based on results. Side effects can be reported to the FDA’s MedWatch program, and patients and clinicians can review the most current prescribing information and safety communications through the FDA and manufacturer websites.

Drug and supplement interactions: Temozolomide has relatively few direct drug–drug interactions through liver enzymes, but other medicines that suppress the bone marrow (such as some chemotherapies, clozapine, or certain antiviral or antibiotic regimens) can increase the risk of low blood counts, and long‑term corticosteroids combined with temozolomide raise the risk of serious infections, sometimes requiring preventive antibiotics.

Food, alcohol, and procedures: Food may slightly affect how quickly temozolomide is absorbed, so many clinicians prefer it on an empty stomach or at bedtime to reduce nausea, though it can sometimes be taken with a light snack if stomach upset is problematic; moderate alcohol use should be discussed with the oncology team because of potential liver strain and worsening fatigue, and temozolomide does not usually interfere with imaging tests but may affect timing of procedures that require good blood counts.

Precautions and conditions: Use requires caution in people with pre‑existing low blood counts, prior intensive chemotherapy or radiation to the bone marrow, active infections, significant liver or kidney disease, or a history of severe allergic reaction to temozolomide or dacarbazine; these conditions may make treatment unsafe or require close monitoring and dose modification.

Monitoring needs: Patients typically need frequent complete blood counts, especially before each cycle and sometimes during the cycle, along with periodic liver and kidney function tests; additional monitoring for infections, lung symptoms, and overall neurologic status is important, and dosing schedules may be adjusted or paused based on results.

Q: How long will I need to take temozolomide?
A: Many people with newly diagnosed glioblastoma take it daily during about 6 weeks of radiation and then for 6 or more monthly cycles afterward, but the exact duration depends on your diagnosis, scan results, side effects, and your oncology team’s plan.

Q: Will I lose my hair with temozolomide?
A: Temozolomide can cause some hair thinning, but for brain tumor patients most hair loss is usually from radiation, and hair often grows back over time after treatment finishes.

Q: What can I do to reduce nausea from temozolomide?
A: Your doctor will usually prescribe anti‑nausea medicine to take before each dose, and taking temozolomide on an empty stomach or at bedtime, sipping clear fluids, and eating small, bland meals can also help.

Q: Is it safe to become pregnant or father a child while on temozolomide?
A: Temozolomide can harm an unborn baby and may affect fertility, so effective birth control is recommended during treatment and for a period afterward, and you should discuss family‑planning questions with your oncology team before starting therapy.

Q: How will I know if temozolomide is working?
A: You generally will not feel an immediate change; your doctor will monitor you with regular brain scans, neurologic exams, and blood tests over months to see whether the tumor is shrinking, stable, or growing and will adjust treatment based on those results.

Storage: Store temozolomide capsules at room temperature, in the original tightly closed container, away from moisture and heat, and out of reach of children and pets.

Handling: Avoid opening capsules; if a capsule breaks, avoid touching the powder with bare hands and wash the area thoroughly if contact occurs.

Disposal: Do not throw unused capsules in household trash or flush them; ask your pharmacy, oncology clinic, or local waste authority about drug take‑back programs or safe hazardous‑drug disposal options.